Claims for Patent: 7,914,785

Summary for Patent: 7,914,785

Title:	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
Abstract:	The present invention relates in a first aspect to a B-cell depleting anti-CD20 antibody or a CD20-binding antibody fragment thereof for the treatment of chronic fatigue syndrome and myalgic encephalomyelitis. In particular, the present invention relates to the use of anti-CD20 monoclonal antibodies or fragments thereof which are preferably humanized for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis in a subject afflicted with said disease.
Inventor(s):	Mella; Olav (Olsvik, NO), Fluge; Oystein (Morvik, NO)
Assignee:	Bergen Teknologieverforing AS (Bergen, NO)
Application Number:	12/348,024
Patent Claims:	1. A method of treating chronic fatigue syndrome and optionally myalgic encephalomyelitis comprising the step of administering a B-cell depleting agent to a subject afflicted therewith. 2. The method for treating chronic fatigue syndrome and myalgic encephalomyelitis as recited in claim 1 wherein said step of administering includes providing said B-cell depleting agent to said subject afflicted therewith one or two infusions twice within two weeks. 3. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 1 wherein said B-cell depleting agent is a B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof, and wherein Methotrexate is administered simultaneously, separately or sequentially with said B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof to said subject. 4. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 2 wherein said B-cell depleting agent is a B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof, and wherein Methotrexate is administered simultaneously, separately or sequentially with said B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof to said subject. 5. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 1, wherein said B-cell depleting agent is a B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof. 6. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 5, wherein said B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof is a monoclonal antibody or CD20-binding antibody fragment thereof. 7. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 5, wherein said B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof is a humanized anti CD20 antibody or CD20-binding antibody fragment thereof. 8. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 5, wherein said B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof is a B-cell depleting CD20 antibody fragment binding to CD20. 9. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 8, wherein said B-cell depleting CD20 antibody fragment is selected from the group consisting of F(ab').sub.2, F(ab'), Fab, Fv and sFv. 10. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 1, wherein said B-cell depleting agent is selected from the group consisting of Rituximab. Ofatumumab, Ocrelizumab, GA101, BCX-301, Veltuzumab, and DXL 625. 11. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 1, wherein said B-cell depleting agent is Rituximab. 12. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 1, wherein said B-cell depleting agent is Methotrexate TRU-015 or SBI-087. 13. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 5, wherein said B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof is administered in an amount in the range of 10 mg to 5000 mg per dosage. 14. The method of treating chronic fatigue syndrome and myalgic encephalomyelitis according to claim 5, wherein said B-cell depleting anti CD20 antibody or CD20-binding antibody fragment thereof is administered to said subject in a single therapeutically effective dosage of said antibody of 50 to 2000 mg/m.sup.2 or multiple of therapeutically effective dosages of said anti CD20 antibody or anti CD20-binding antibody fragment thereof of 50 to 2000 mg/m.sup.2.

Details for Patent 7,914,785

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-02-26
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2039-02-26
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10/26/2009		2039-02-26